Efficacy and Safety of Saroglitazar and Vitamin E in NAFLD Related Compensated Advanced Chronic Liver Disease. - Not applicable

PGIMER0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年3月4日

试验速览

暂无简介。

•1.Age18-75years
•2.Patients with NAFLD: Defined by the presence of hepatic steatosis on ultrasound or using CAP parameters (of FibroScan) in absence significant consumption of alcohol ( <20g/day irrespective of gender) after ruling out other etiologies for hepatic steatosis or elevated transaminases including but not limited to chronic viral hepatitis, autoimmune Hepatitis, hemochromatosis, Wilson disease, celiac disease, Drug induced liver injury (DILI), etc.
•3.Patients with LSM > 10kPa
•4.Consent to participate in study

•1.Patients <18years of age
•2.Patients with Hepatic decompensation
•3.Patients with HCC or any other malignancy
•4.Patients with concomitant other aetiologies for hepatic steatosis/fibrosis or elevated transaminases
•5.Patients already on Vitamin E or pioglitazone
•6.Pregnancy/Lactation and those non pregnant female patients recruited in the study who will conceive during the study period will be excluded from the study.
•7.Patients who are too sick to conduct the protocol.
•8.Those who do not consent to participate in the study.

发起方